Difference between revisions of "Axitinib (Inlyta)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Tyrosine kinase inhibitor of | + | Class/mechanism: Tyrosine kinase inhibitor of vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression, at picomolar concentrations. Inhibits PDGFRA, PDGFRB and c-kit at nanomolar concentrations.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=759 Axitinib (Inlyta) package insert]</ref><ref>[[Media:Axitinib.pdf | Axitinib (Inlyta) package insert (locally hosted backup)]]</ref><ref>Matthew Stenger. [http://www.ascopost.com/articles/march-15-2012/what-you-need-to-know-about-axitinib/ What You Need to Know About Axitinib, New Agent for Treating Advanced Renal Cell Carcinoma]. ASCO Post, March 15, 2012, Volume 3, Issue 5.</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 16: | Line 14: | ||
*[http://chemocare.com/chemotherapy/drug-info/axitinib.aspx Axitinib (Inlyta) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/axitinib.aspx Axitinib (Inlyta) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/axitinib.aspx Axitinib (Inlyta) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/axitinib.aspx Axitinib (Inlyta) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/axitinib-patient-drug-information Axitinib (Inlyta) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/axitinib-patient-drug-information Axitinib (Inlyta) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/axitinib-patient-drug-information Axitinib (Inlyta) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/axitinib-patient-drug-information Axitinib (Inlyta) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 1/27/2012: Initial FDA approval "for the treatment of advanced [[Renal cancer | renal cell carcinoma]] after failure of one prior systemic therapy." | ||
| + | |||
| + | ==Also known as== | ||
| + | AG013736 | ||
==References== | ==References== | ||
| Line 22: | Line 26: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| + | [[Category:Oral chemotherapy]] | ||
| + | |||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
| + | [[Category:KIT inhibitors]] | ||
| + | [[Category:PDGFR inhibitors]] | ||
[[Category:VEGF inhibitors]] | [[Category:VEGF inhibitors]] | ||
| − | |||
| − | |||
[[Category:Renal cancer medications]] | [[Category:Renal cancer medications]] | ||
[[Category:Thyroid cancer medications]] | [[Category:Thyroid cancer medications]] | ||
[[Category:Drugs FDA approved in 2012]] | [[Category:Drugs FDA approved in 2012]] | ||
Revision as of 02:36, 17 November 2014
General information
Class/mechanism: Tyrosine kinase inhibitor of vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression, at picomolar concentrations. Inhibits PDGFRA, PDGFRB and c-kit at nanomolar concentrations.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Axitinib (Inlyta) patient drug information (Pfizer)[4]
- Axitinib (Inlyta) patient drug information (Chemocare)[5]
- Axitinib (Inlyta) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 1/27/2012: Initial FDA approval "for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy."
Also known as
AG013736
References
- ↑ 1.0 1.1 Axitinib (Inlyta) package insert
- ↑ Axitinib (Inlyta) package insert (locally hosted backup)
- ↑ Matthew Stenger. What You Need to Know About Axitinib, New Agent for Treating Advanced Renal Cell Carcinoma. ASCO Post, March 15, 2012, Volume 3, Issue 5.
- ↑ Axitinib (Inlyta) patient drug information (Pfizer)
- ↑ Axitinib (Inlyta) patient drug information (Chemocare)
- ↑ Axitinib (Inlyta) patient drug information (UpToDate)